Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers

　　Trodelvy®(Sacituzumab Govitecan-hziy)is a transformative antibody-drug conjugate(ADC)designed to target the human trop-2 cell surface antigen,offering targeted treatment for aggressive cancers.This therapy combines precision targeting with potent cytotoxic action,making it a vital option for patients with limited treatment choices.

　　1.Key Indications:

　　●Metastatic Triple-Negative Breast Cancer(mTNBC):Approved for patients who have received at least two prior systemic therapies.Trodelvy has demonstrated significant progression-free survival(PFS)and overall survival(OS)benefits.

　　●Urothelial Carcinoma:Indicated for patients with advanced disease who have progressed on platinum-based chemotherapy and PD-1/PD-L1 inhibitors.

　　●Trop-2 Positive Solid Tumors:An emerging treatment option for other cancers expressing the Trop-2 antigen.

　　2.Mechanism of Action:

　　Trodelvy consists of an anti-Trop-2 monoclonal antibody conjugated to SN-38,a potent camptothecin derivative.Upon binding to Trop-2 overexpressed on cancer cells,the ADC is internalized,releasing SN-38 to induce DNA damage and cell death,sparing healthy tissues.

　　3.Contraindications:

　　●Hypersensitivity to Sacituzumab Govitecan or its components.

　　●Pregnancy(potential fetal harm).

　　●Severe hepatic impairment(bilirubin>3x ULN).

　　●Concurrent use with strong UGT1A1 inhibitors.

　　4.High-Risk Populations:

　　●Elderly(≥75 years):Increased risk of neutropenia and diarrhea;monitor closely.

　　●Mild-Moderate Hepatic Impairment:No dose adjustment required for bilirubin≤1.5x ULN.

　　●Patients with Prior Intensive Chemotherapy:Risk of myelosuppression;monitor blood counts regularly.

　　●Active Infections:Delay treatment until resolved.

　　5.Common&Serious Adverse Reactions:

　　●Grade≥3 Adverse Events:Neutropenia(29%),diarrhea(15%),fatigue(14%).

　　●Other Frequent Side Effects:Nausea,vomiting,anemia,hair loss.

　　●Life-Threatening Reactions:Severe neutropenia,diarrhea-induced dehydration,interstitial lung disease(ILD).

　　6.Administration&Monitoring:

　　●Dosing:10 mg/kg IV infusion on Days 1 and 8 of a 21-day cycle.

　　●Pre-Medication:Antiemetics and antipyretics to prevent infusion reactions.

　　●Monitoring:Weekly blood counts,LFTs,and clinical assessments for toxicity.

　　●Dose Modifications:Reduce dose or delay for Grade 3-4 toxicities;discontinue for recurrent severe events.

　　Global Availability&Cost:

　　Trodelvy is commercially available in multiple regions,with costs varying by market.Prices range approximately US$2,000–3,000 per vial,aligning with therapeutic value in advanced cancer care.Generic versions are not currently marketed.